Mindray Jumps Into Orthopedic Space With Sixth Acquisition In Last 18 Months
This article was originally published in PharmAsia News
China’s leading medical device company enters the orthopedic market with a $35.5 million acquisition of domestic player Dragonbio.
You may also be interested in...
SHANGHAI - China's leading medical device company Mindray's third quarter report disappointed investors again with an 11.3% increase in revenue over the same period last year to $168 million, which missed Street expectations of $170-178 million. Weak sales in China are the culprit for slow growth, even as the company sees significant gains in other emerging markets
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.
China is planning a new regulation on company employees’ “service innovation” designed to encourage inventors and invention in the country, which are seen as important contributors to economic growth. However, the new rules could also have a significant impact on the conduct of drug discovery research in China.